dalnacogene ponparvovec

AXP000256.1 · Viral vector gene therapy

Platform
AAV vector (capsid not stated in the sources seen)
Targets
F9
Originator
Belief BioMed
Sponsor
Belief BioMed

Names

NameTypeSource
dalnacogene ponparvovecpreferred namecurator
XinJiuningbrandpress
BBM-H901codepress

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus
Replication
non replicating
Transgenes
F9
Route
intravenous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
NMPACN2025-04approvedXinJiuningAdults with moderate to severe haemophilia B (congenital factor IX deficiency)source
otherMO2026-03approvedXinJiuningAdults with moderate to severe haemophilia B, approved by Macao's Pharmaceutical Administration Bureausource

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldRecruitingPhase 12023-03-232035-069Hemophilia B
Unconfirmed matches (2)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT05203679Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy DrugActive not recruitingPhase 2/32021-12-302024-04-1632Hemophilia Bname in intervention: BBM-H901
NCT04135300Gene Therapy for Chinese Hemophilia BCompleted2019-10-162022-01-0710Hemophilia Bname in intervention: BBM-H901

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41266685Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials.Nature medicine2026name in abstract: BBM-H901
PMID 42749889Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial.Nature medicine2026cited by trial NCT05709288
PMID 35598604Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.The Lancet. Haematology2022name in abstract: BBM-H901

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41381305Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.Blood reviews2026name in abstract: dalnacogene ponparvovec
PMID 42984386Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products.Haematologica2026name in abstract: dalnacogene ponparvovec
PMID 41180128Chinese guidance for the clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025).Blood science (Baltimore, Md.)2025name in abstract: dalnacogene ponparvovec

Notes

China's first approved rAAV gene therapy and its first for a rare disease: an AAV vector delivering an optimised factor IX gene to hepatocytes, approved by the NMPA in April 2025 for adults with moderate to severe haemophilia B, with Takeda China commercialising it. Approved in Macao in March 2026. Brand name XinJiuning. The capsid serotype is not given in the sources seen, so `strain` is empty.

How to cite

dalnacogene ponparvovec (AXP000256.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000256.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.